What is Polymixin Market Scope?
Polymyxins are a class of gold standard antibiotics against resistant Gram-negative infections and are commonly used in the treatment of oral mucositis. The increasing incidence of infections due to multidrug-resistant gram-negative bacteria is one the key driver booming the growth of the market.
The Polymixin market study is being classified by Type (Polymyxin B and Polymyxin E), by Application (Humans and Veterinary {Pigs, Poultry, Cattle, Sheep, Goats, Rabbits, and Others}) and major geographies with country level break-up.
Analysts at AMA predicts that Players from Chinese will contribute to the maximum growth of Global Polymixin market throughout the predicted period.
Northern Antibiotics Ltd (Finland), Aurobindo Pharma (India), Xellia (Denmark), Huazhong Pharmaceutical Co., Ltd (HPC) (China), Merck KGaA (Germany), Hebei Veyong Animal Pharmaceutical Co., Ltd (China), Livzon Group (China), Hebei Shengxue Dacheng (China), Lifecome Biochemistry (China) and Zhejiang Apeloa Kangyu BioPharmaceutical (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Meiji Pharma (China) and Kyowa Hakko Bio (Japan).
Segmentation Analysis
Analyst at AMA have segmented the market study of Global Polymixin market by Type, Application and Region.
On the basis of geography, the market of Polymixin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Influencers and their development strategies
On 30 2019, Qpex Biopharma announced the closing of a license agreement from Monash University providing Qpex a portfolio of next-generation polymyxin antimicrobials focused against highly drug-resistant gram-negative pathogens. The exclusive license includes worldwide rights to develop and commercialize polymyxin antimicrobials in multiple territories.
On 21 Aug 2019, Finnish virtual antibiotics developer Northern Antibiotics is working towards a new molecule that targets drug-resistant bacteria. Northern Antibiotics’ new molecule is a polymyxin derivative belonging to the peptide antibiotics and is effective against carbapenem-resistant bacteria. and In 2016, Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Polymyxin B for Injection USP, 500,000 units/vial.
On 21 July 2019, the Health Ministry of India has banned the manufacture, sale and distribution of antibiotic, Colistin and its formulations for food producing animals, poultry, aqua farming and animal feed supplements in a bid to preserve the drug’s efficacy in humans. The ban has been imposed under provisions of the Drugs and Cosmetics Act, 1940 and a notification in this regard has been issued by the Centre.
Influencing Market Trend
- Continuous Research & Developments in Polymixins
Market Drivers
- The Increasing Incidence of Infections Due To Multidrug-Resistant Gram-Negative Bacteria
- The Lack of New Antibacterial Agents
Opportunities
- Development of Novel Polymyxins That Will Be Safer and Efficacious
Restraints
- The Effective Use of Polymyxins in the Clinic Has Been Hampered By Their Nephrotoxic Side Effects
Key Target Audience
Polymixin Manufacturers, Polymixin Traders/Distributors, Polymixin Importer/Exporter, Regulatory & Government Bodies, End Users and Others
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.